TBL1XR1 induces cell proliferation and inhibit cell apoptosis by the PI3K/AKT pathway in pancreatic ductal adenocarcinoma

Table 2 Univariate log-rank analysis of overall survival

Parameter	Category	Case number	Median survival time (mo)	P value
			(95%CI)
Age (yrs)	< 60	40	10.0 (4.8-15.2)	0.413
	≥ 60	50	9.7 (7.41–12.0)
Sex	Male	59	9.9 (6.7-13.1)	0.983
	Female	31	9.9 (8.1-12.0)
Histopathological subtypes	High	3	25.0 (-)	0.760
	Middle	51	10.3 (8.1–11.7)
	Low	36	8.7 (6.0-11.4)
TNM stage	1-II	12	25.0 (18.1-31.9)	< 0.001c
	III-IV	78	8.0 (5.5-10.5)
Tumor size	< 3 cm	60	9.8 (8.6-11.0)	0.251
	≥ 3 cm	30	8.3 (4.8-11.8)
Tumor location	Head	37	9.3 (7.0-11.7)	0.095
	Body/tail	53	11.0 (6.0-16.0)
Lymph node metastasis	Negative	61	12.0 (7.9-16.1)	0.047a
	Positive	29	7.6 (5.3-9.8)
TBL1XR1 expression	Low	27	18.9 (10.9-26.9)	< 0.001c
	High	63	7.0 (5.7-8.3)

^aP < 0.05,

^cP < 0.001. TBL1XR1: Transducin (β)-like 1 X-linked receptor 1; CI: Confidence interval; TNM: Tumor-node-metastasis.